Your browser doesn't support javascript.
loading
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
Gogola, Ewa; Duarte, Alexandra A; de Ruiter, Julian R; Wiegant, Wouter W; Schmid, Jonas A; de Bruijn, Roebi; James, Dominic I; Guerrero Llobet, Sergi; Vis, Daniel J; Annunziato, Stefano; van den Broek, Bram; Barazas, Marco; Kersbergen, Ariena; van de Ven, Marieke; Tarsounas, Madalena; Ogilvie, Donald J; van Vugt, Marcel; Wessels, Lodewyk F A; Bartkova, Jirina; Gromova, Irina; Andújar-Sánchez, Miguel; Bartek, Jiri; Lopes, Massimo; van Attikum, Haico; Borst, Piet; Jonkers, Jos; Rottenberg, Sven.
Afiliação
  • Gogola E; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, Amsterdam 1066CX, the Netherlands.
  • Duarte AA; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, Amsterdam 1066CX, the Netherlands.
  • de Ruiter JR; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, Amsterdam 1066CX, the Netherlands.
  • Wiegant WW; Department of Human Genetics, Leiden University Medical Center, Leiden 2333 ZC, the Netherlands.
  • Schmid JA; Institute of Molecular Cancer Research, University of Zurich, Zurich CH-8057, Switzerland.
  • de Bruijn R; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, Amsterdam 1066CX, the Netherlands.
  • James DI; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Manchester M20 4BX, UK.
  • Guerrero Llobet S; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen 9723GZ, the Netherlands.
  • Vis DJ; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, Amsterdam 1066CX, the Netherlands.
  • Annunziato S; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, Amsterdam 1066CX, the Netherlands.
  • van den Broek B; Division of Cell Biology and BioImaging Facility, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands.
  • Barazas M; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, Amsterdam 1066CX, the Netherlands.
  • Kersbergen A; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands.
  • van de Ven M; Mouse Clinic for Cancer and Aging (MCCA), Preclinical Intervention Unit, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands.
  • Tarsounas M; CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK.
  • Ogilvie DJ; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Manchester M20 4BX, UK.
  • van Vugt M; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen 9723GZ, the Netherlands.
  • Wessels LFA; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, Amsterdam 1066CX, the Netherlands.
  • Bartkova J; Danish Cancer Society Research Center, Copenhagen 2100, Denmark; Karolinska Institute, Department of Medical Biochemistry and Biophysics, Division of Genome Biology, Science for Life Laboratory, Stockholm 171 77, Sweden.
  • Gromova I; Danish Cancer Society Research Center, Copenhagen 2100, Denmark.
  • Andújar-Sánchez M; Pathology Department, Complejo Hospt. Univ. Insular Materno Infantil, Las Palmas, Gran Canaria, Spain.
  • Bartek J; Danish Cancer Society Research Center, Copenhagen 2100, Denmark; Karolinska Institute, Department of Medical Biochemistry and Biophysics, Division of Genome Biology, Science for Life Laboratory, Stockholm 171 77, Sweden.
  • Lopes M; Institute of Molecular Cancer Research, University of Zurich, Zurich CH-8057, Switzerland.
  • van Attikum H; Department of Human Genetics, Leiden University Medical Center, Leiden 2333 ZC, the Netherlands.
  • Borst P; Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands.
  • Jonkers J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Cancer Genomics Netherlands, Oncode Institute, Amsterdam 1066CX, the Netherlands. Electronic address: j.jonkers@nki.nl.
  • Rottenberg S; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam 1066CX, the Netherlands; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern 3012, Switzerland. Electronic address: sven.rottenberg@vetsuisse.unibe.ch.
Cancer Cell ; 33(6): 1078-1093.e12, 2018 06 11.
Article em En | MEDLINE | ID: mdl-29894693
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Poli(ADP-Ribose) Polimerases / Poli(ADP-Ribose) Polimerase-1 / Mutações Sintéticas Letais / Glicosídeo Hidrolases Limite: Animals / Female / Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Poli(ADP-Ribose) Polimerases / Poli(ADP-Ribose) Polimerase-1 / Mutações Sintéticas Letais / Glicosídeo Hidrolases Limite: Animals / Female / Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos